Literature DB >> 22763792

Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

John Heineman1, Sara Bubenik, Stephen McClave, Robert Martindale.   

Abstract

Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilator-associated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763792     DOI: 10.1007/s11894-012-0274-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  47 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease.

Authors:  Lynne V McFarland
Journal:  Am J Gastroenterol       Date:  2006-04       Impact factor: 10.864

Review 3.  Perspectives in surgical infections: what does the future hold?

Authors:  Lena M Napolitano
Journal:  Surg Infect (Larchmt)       Date:  2010-04       Impact factor: 2.150

4.  Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.

Authors:  Alona Bin-Nun; Ruben Bromiker; Michael Wilschanski; Michael Kaplan; Bernard Rudensky; Michael Caplan; Cathy Hammerman
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

5.  Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

Authors:  J L Tong; Z H Ran; J Shen; C X Zhang; S D Xiao
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

6.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

7.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

8.  A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.

Authors:  Victoria Hurduc; Doina Plesca; Dimitrie Dragomir; Maria Sajin; Yvan Vandenplas
Journal:  Acta Paediatr       Date:  2008-08-04       Impact factor: 2.299

9.  Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.

Authors:  Mehmet Cindoruk; Gulbanu Erkan; Tarkan Karakan; Ayse Dursun; Selahattin Unal
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

10.  Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study.

Authors:  Bengt Klarin; Göran Molin; Bengt Jeppsson; Anders Larsson
Journal:  Crit Care       Date:  2008-11-06       Impact factor: 9.097

View more
  9 in total

Review 1.  Bugs or drugs: are probiotics safe for use in the critically ill?

Authors:  Lindsay M Urben; Jennifer Wiedmar; Erica Boettcher; Rodrigo Cavallazzi; Robert G Martindale; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2014

2.  Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.

Authors:  Karishma Kamdar; Samira Khakpour; Jingyu Chen; Vanessa Leone; Jennifer Brulc; Thomas Mangatu; Dionysios A Antonopoulos; Eugene B Chang; Stacy A Kahn; Barbara S Kirschner; Glenn Young; R William DePaolo
Journal:  Cell Host Microbe       Date:  2016-01-13       Impact factor: 21.023

Review 3.  Vaccine against Helicobacter pylori: Inevitable approach.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 4.  Microbial regulation of allergic responses to food.

Authors:  Taylor Feehley; Andrew T Stefka; Severine Cao; Cathryn R Nagler
Journal:  Semin Immunopathol       Date:  2012-09-01       Impact factor: 9.623

Review 5.  Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.

Authors:  Alexander A Nijevitch; Bulat Idrisov; Elsa N Akhmadeeva; David Y Graham
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota.

Authors:  P Carasi; S M Racedo; C Jacquot; D E Romanin; M A Serradell; M C Urdaci
Journal:  J Immunol Res       Date:  2015-02-24       Impact factor: 4.818

Review 7.  A current update on the rule of alternative and complementary medicine in the treatment of liver diseases.

Authors:  Yong-Song Guan; Qing He
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-10       Impact factor: 2.629

8.  Colonization with Escherichia coli EC 25 protects neonatal rats from necrotizing enterocolitis.

Authors:  Debi M Thomas; Brandon Bell; Stephanie Papillon; Patrick Delaplain; Joanna Lim; Jamie Golden; Jordan Bowling; Jin Wang; Larry Wang; Anatoly V Grishin; Henri R Ford
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

9.  Loss of CNFY toxin-induced inflammation drives Yersinia pseudotuberculosis into persistency.

Authors:  Wiebke Heine; Michael Beckstette; Ann Kathrin Heroven; Sophie Thiemann; Ulrike Heise; Aaron Mischa Nuss; Fabio Pisano; Till Strowig; Petra Dersch
Journal:  PLoS Pathog       Date:  2018-02-01       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.